Skip to main content

Vericel Corporation (VCEL)

NASDAQ: VCEL · IEX Real-Time Price · USD
38.31 -1.88 (-4.68%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap1.79B
Revenue (ttm)153.82M
Net Income (ttm)214,000
Shares Out46.82M
EPS (ttm)0.01
PE Ratio7,662.00
Forward PE67.11
Dividendn/a
Ex-Dividend Daten/a
Volume372,722
Open42.50
Previous Close40.19
Day's Range37.37 - 40.71
52-Week Range22.93 - 68.94
Beta1.94
AnalystsStrong Buy
Price Target58.96 (+53.9%)
Earnings DateNov 9, 2021

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-de...

IndustryBiotechnology
IPO DateFeb 4, 1997
CEODominick Colangelo
Employees273
Stock ExchangeNASDAQ
Ticker SymbolVCEL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for Vericel stock is "Strong Buy." The 12-month stock price forecast is 58.96, which is an increase of 53.90% from the latest price.

Price Target
$58.96
(53.90% upside)
Analyst Consensus: Strong Buy

News

Vericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on Nov...

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

2 weeks ago - GlobeNewsWire

Vericel Corporation (VCEL) Reports Q3 Loss, Misses Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -266.67% and -11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Recap: Vericel Q3 Earnings

Vericel (NASDAQ:VCEL) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

2 weeks ago - Benzinga

Vericel Reports Third Quarter 2021 Financial Results

Third Quarter Total Net Revenue of $34.5 Million

2 weeks ago - GlobeNewsWire

Earnings Preview: Vericel Corporation (VCEL) Q3 Earnings Expected to Decline

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

Vericel to Report Third-Quarter 2021 Financial Results on November 9, 2021

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following ...

1 month ago - GlobeNewsWire

How to Invest in Biotech Stocks in a Bear Market

Hint: it doesn't really matter what kind of market it is.

Other symbols:CPRXCRSP
1 month ago - The Motley Fool

Vericel Expands Executive Leadership Team and Announces Appointment of Patrick Fowler as Senior Vice President, Corpo...

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of ...

2 months ago - GlobeNewsWire

Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -33.33% and 7.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Vericel Reports Second Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance

Second Quarter Total Net Revenue Increased 97% to $39.5 Million

3 months ago - GlobeNewsWire

Will Vericel Corporation (VCEL) Report Negative Earnings Next Week? What You Should Know

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021

CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following ...

4 months ago - GlobeNewsWire

Bear of the Day: Vericel (VCEL)

Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside

4 months ago - Zacks Investment Research

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vericel Corporation - VCEL

NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vericel Corporation ("Vericel" or the "Company") (NASDAQ: VCEL).  Such investors are advised to co...

4 months ago - PRNewsWire

Vericel to Present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

4 months ago - GlobeNewsWire

Why Vericel Tumbled by Nearly 15% on Tuesday

The FDA says "no" to the company's NexoBrid -- for now.

4 months ago - The Motley Fool

Why Shares Of MediWound And Vericel Fell On Tuesday

Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Bi...

Other symbols:MDWD
4 months ago - Benzinga

FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop

Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar removal ...

Other symbols:MDWD
4 months ago - Benzinga

Vericel Provides Regulatory Update for NexoBrid

CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its devel...

4 months ago - GlobeNewsWire

Vericel to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

5 months ago - GlobeNewsWire

Vericel Announces Appointment of Lisa Wright to Board of Directors

CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointmen...

5 months ago - GlobeNewsWire

Vericel to Present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colan...

6 months ago - GlobeNewsWire

Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 8.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Recap: Vericel Q1 Earnings

Shares of Vericel (NASDAQ:VCEL) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 30.00% year over year to ($0.07), which missed the estimate of ($0.04).

6 months ago - Benzinga

Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance

First Quarter Total Net Revenue Increased 30% to $34.6 Million

6 months ago - GlobeNewsWire